PHVS vs PVLA: fair value comparison
Pharvaris N.V. and Palvella Therapeutics, Inc. · Updated 2026-10-19
PHVS reports in EUR, so no same-currency fair-value verdict is published for it. PVLA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, PHVS currently ranks higher by quality score.
| PHVS | PVLA | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $31.01 | $120.30 |
| 12-month range | $21.59–$38.86 | $70.43–$158.13 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #261 of 301 Healthcare | #262 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Expanding |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: PHVS fair value analysis · PVLA fair value analysis